Does Sophiris Bio Inchares (NASDAQ:SPHS) Have Gas After Even Less Sellers Involved?

June 11, 2018 - By Darrin Black

Sophiris Bio, Inc. (NASDAQ:SPHS) Logo

Investors sentiment decreased to 1 in 2018 Q1. Its down 1.80, from 2.8 in 2017Q4. It dropped, as 5 investors sold Sophiris Bio, Inc. shares while 5 reduced holdings. 5 funds opened positions while 5 raised stakes. 1.63 million shares or 13.01% less from 1.87 million shares in 2017Q4 were reported.
B & T Mngmt Dba Alpha Mngmt reported 23,228 shares or 0.02% of all its holdings. Northern Trust reported 20,508 shares. Morgan Stanley accumulated 5,000 shares. Wells Fargo & Mn holds 1,800 shares or 0% of its portfolio. Blackrock has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Bancorporation Of Ny Mellon Corp invested in 36,890 shares or 0% of the stock. Virtu Ltd Llc, a New York-based fund reported 33,712 shares. Barclays Public Limited Com holds 1 shares. Susquehanna Intl Llp has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 33,187 shares. Lpl Lc reported 10,000 shares. Millennium Ltd has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 104,627 shares. Comml Bank Of Montreal Can invested in 11,210 shares or 0% of the stock. Group One Trading L P has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). 800 were accumulated by Architects Inc. Bancorp Of America Corp De accumulated 3,338 shares.

The stock of Sophiris Bio Inchares (NASDAQ:SPHS) registered a decrease of 3.07% in short interest. SPHS’s total short interest was 1.79M shares in June as published by FINRA. Its down 3.07% from 1.85M shares, reported previously. With 295,900 shares average volume, it will take short sellers 6 days to cover their SPHS’s short positions. The short interest to Sophiris Bio Inchares’s float is 6.29%.

The stock increased 2.13% or $0.08 during the last trading session, reaching $3.83. About 648,487 shares traded or 79.33% up from the average. Sophiris Bio, Inc. (NASDAQ:SPHS) has risen 44.13% since June 11, 2017 and is uptrending. It has outperformed by 31.56% the S&P500.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $110.04 million. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

Sophiris Bio, Inc. (NASDAQ:SPHS) Ratings Coverage

Among 2 analysts covering Sophiris Bio (NASDAQ:SPHS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sophiris Bio has $700 highest and $600 lowest target. $6.50’s average target is 69.71% above currents $3.83 stock price. Sophiris Bio had 4 analyst reports since January 17, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Friday, May 18 by Piper Jaffray. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Wednesday, January 17 report. The firm has “Buy” rating given on Thursday, March 22 by H.C. Wainwright. The stock of Sophiris Bio, Inc. (NASDAQ:SPHS) earned “Buy” rating by H.C. Wainwright on Tuesday, May 15.

Sophiris Bio, Inc. (NASDAQ:SPHS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: